Vaflard, Pauline
Paoletti, Xavier
Servois, Vincent
Tresca, Patricia
Pons-Tostivint, Elvire
Sablin, Marie-Paule
Ricci, Francesco
Loirat, Delphine
Hescot, Ségolène
Torossian, Nouritza
Bello Roufai, Diana
Kamal, Maud
Borcoman, Edith
Le Tourneau, Christophe http://orcid.org/0000-0001-9772-4686
Article History
Accepted: 1 September 2021
First Online: 25 September 2021
Declarations
:
: None declared.
: Christophe Le Tourneau has participated in advisory boards from MSD, BMS, Merck Serono, Astra Zeneca, Roche, Amgen, Nanobiotix, GSK, Celgene, and Rakuten. Delphine Loirat has participated in advisory boards from MSD, Roche, BMS, Astra Zeneca, Novartis, and Nanobiotix. The other authors have declared no conflicts of interest.
: All patients included in the study were included in a clinical trial and treated at the Curie Institute. Our study pertaining to these patients received approval from the Institutional Review Committee of Curie Institute (OBS200216). The study was performed in accordance with the Declaration of Helsinki.
: All patients signed an informed consent to be treated.
: Not applicable.
: All data are available at the Curie Institute upon request of the corresponding author.
: Not applicable.
: PV, CLT and XP designed the study. XP made the statistical analyses. PV and CLT wrote the manuscript. All authors reviewed the manuscript.